Works matching DE "BRUTON tyrosine kinase"
Results: 749
Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node.
- Published in:
- Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1548102
- By:
- Publication type:
- Article
Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma.
- Published in:
- Technology in Cancer Research & Treatment, 2025, p. 1, doi. 10.1177/15330338251319394
- By:
- Publication type:
- Article
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.
- Published in:
- Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2024.1369619
- By:
- Publication type:
- Article
Multifocal Myelitis Associated with Chronic Lymphocytic Leukemia.
- Published in:
- Canadian Journal of Neurological Sciences, 2025, v. 52, n. 2, p. 335, doi. 10.1017/cjn.2024.275
- By:
- Publication type:
- Article
Bruton's tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01214-y
- By:
- Publication type:
- Article
Development, validation, and clinical application of LC-MS/MS method for simultaneous determination of ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, and their active metabolites in patients with B-cell lymphoma.
- Published in:
- Analytical & Bioanalytical Chemistry, 2025, v. 417, n. 4, p. 821, doi. 10.1007/s00216-024-05701-2
- By:
- Publication type:
- Article
Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.
- Published in:
- Molecular Medicine, 2022, v. 28, n. 1, p. 1, doi. 10.1186/s10020-022-00518-0
- By:
- Publication type:
- Article
Dual-pathway inhibition in patients with chronic limb-threatening ischemia requiring reintervention for infrapopliteal occlusions.
- Published in:
- Heart & Vessels, 2024, v. 39, n. 9, p. 771, doi. 10.1007/s00380-024-02406-5
- By:
- Publication type:
- Article
BTK inhibition limits B-cell–T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy.
- Published in:
- Acta Neuropathologica, 2022, v. 143, n. 4, p. 505, doi. 10.1007/s00401-022-02411-w
- By:
- Publication type:
- Article
Anaphylaxie: Das Potenzial von BTK-Inhibitoren bei der Behandlung von Nahrungsmittelallergien.
- Published in:
- Kompass Dermatologie, 2024, v. 12, n. 4, p. 214, doi. 10.1159/000542071
- By:
- Publication type:
- Article
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00379-8
- By:
- Publication type:
- Article
The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils.
- Published in:
- Nature Immunology, 2012, v. 13, n. 4, p. 369, doi. 10.1038/ni.2234
- By:
- Publication type:
- Article
Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis.
- Published in:
- Postepy Psychiatrii i Neurologii / Advances in Psychiatry & Neurology, 2023, v. 32, n. 1, p. 23, doi. 10.5114/ppn.2023.126319
- By:
- Publication type:
- Article
Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 4, p. 363, doi. 10.1007/s10384-023-00997-6
- By:
- Publication type:
- Article
Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2022, v. 37, n. 1, p. 226, doi. 10.1080/14756366.2021.1999237
- By:
- Publication type:
- Article
Discovery of new symmetrical and asymmetrical nitrile-containing 1,4-dihydropyridine derivatives as dual kinases and P-glycoprotein inhibitors: synthesis, in vitro assays, and in silico studies.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2022, v. 37, n. 1, p. 2489, doi. 10.1080/14756366.2022.2120478
- By:
- Publication type:
- Article
Campylobacter infection in 4 patients treated with ibrutinib.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.
- Published in:
- eLife, 2024, p. 1, doi. 10.7554/eLife.95488
- By:
- Publication type:
- Article
Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-47735-z
- By:
- Publication type:
- Article
Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-44956-0
- By:
- Publication type:
- Article
Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-36279-x
- By:
- Publication type:
- Article
Zanubrutinib-induced aseptic meningitis: a case report and literature review.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1242491
- By:
- Publication type:
- Article
Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL.
- Published in:
- Frontiers in Pharmacology, 2023, p. 01, doi. 10.3389/fphar.2023.1229304
- By:
- Publication type:
- Article
Older Adults and Immune Thrombocytopenia: Considerations for the Clinician.
- Published in:
- Clinical Interventions in Aging, 2023, v. 18, p. 115, doi. 10.2147/CIA.S369574
- By:
- Publication type:
- Article
Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review.
- Published in:
- Blood & Lymphatic Cancer: Targets & Therapy, 2023, v. 13, p. 67, doi. 10.2147/BLCTT.S426588
- By:
- Publication type:
- Article
Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.
- Published in:
- Blood & Lymphatic Cancer: Targets & Therapy, 2022, v. 12, p. 81, doi. 10.2147/BLCTT.S326627
- By:
- Publication type:
- Article
Progression of Sclerouveitis to Endogenous Fusarium Endophthalmitis.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse.
- Published in:
- Case Reports in Hematology, 2022, p. 1, doi. 10.1155/2022/1930546
- By:
- Publication type:
- Article
Reactivation of Coccidioides immitis in a Prosthetic Knee after Initiation of Chemotherapy.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
FcγRIIB mediates antigen-independent inhibition on human B lymphocytes through Btk and p38 MAPK.
- Published in:
- Journal of Biomedical Science, 2015, v. 22, p. 1, doi. 10.1186/s12929-015-0200-9
- By:
- Publication type:
- Article
Outlook of the jakinibs in systemic lupus erythematous after baricitinib failed.
- Published in:
- International Journal of Rheumatic Diseases, 2024, v. 27, n. 2, p. 1, doi. 10.1111/1756-185X.15082
- By:
- Publication type:
- Article
Intention to treat: The management of connective tissue disease‐related immune thrombocytopenia.
- Published in:
- International Journal of Rheumatic Diseases, 2023, v. 26, n. 10, p. 1885, doi. 10.1111/1756-185X.14811
- By:
- Publication type:
- Article
Le lymphome vitréorétinien primitif.
- Published in:
- Hematologie, 2024, v. 30, n. 4, p. 245, doi. 10.1684/hma.2024.1859
- By:
- Publication type:
- Article
Activation du récepteur des lymphocytes B : mécanismes moléculaires et cibles thérapeutiques.
- Published in:
- Hematologie, 2023, v. 29, n. 3, p. 171, doi. 10.1684/hma.2023.1813
- By:
- Publication type:
- Article
Dix ans d'avancées dans le lymphome à cellules du manteau : des thérapies ciblées à l'ingénierie cellulaire.
- Published in:
- Hematologie, 2023, v. 29, p. 36, doi. 10.1684/hma.2023.1809
- By:
- Publication type:
- Article
Leucémie lymphoïde chronique : une décennie de thérapies ciblées.
- Published in:
- Hematologie, 2023, v. 29, p. 23, doi. 10.1684/hma.2023.1807
- By:
- Publication type:
- Article
Toxicité des inhibiteurs de la tyrosine kinase de Bruton au niveau cardiovasculaire.
- Published in:
- Hematologie, 2023, v. 29, p. 44, doi. 10.1684/hma.2023.1775
- By:
- Publication type:
- Article
Traitement en 2022 de la leucémie à tricholeucocytes et de sa forme variante.
- Published in:
- Hematologie, 2022, v. 28, n. 2, p. 116, doi. 10.1684/hma.2022.1751
- By:
- Publication type:
- Article
Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy.
- Published in:
- Virology Journal, 2023, v. 20, n. 1, p. 1, doi. 10.1186/s12985-023-02140-w
- By:
- Publication type:
- Article
Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma.
- Published in:
- Cancer Cell International, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12935-021-01891-2
- By:
- Publication type:
- Article
Brexucabtagene autoleucel.
- Published in:
- Australian Prescriber, 2023, v. 46, n. 2, p. 40, doi. 10.18773/austprescr.2023.011
- Publication type:
- Article
Zanubrutinib.
- Published in:
- Australian Prescriber, 2022, v. 45, n. 1, p. 34, doi. 10.18773/austprescr.2021.066
- Publication type:
- Article
Treatment selection and influencing factors for chronic lymphocytic leukemia: a physician survey in Japan.
- Published in:
- International Journal of Clinical Oncology, 2025, v. 30, n. 1, p. 157, doi. 10.1007/s10147-024-02645-6
- By:
- Publication type:
- Article
Screening, Synthesis and Biological Evaluation of Novel Bruton's Tyrosine Kinase Inhibitors.
- Published in:
- Pharmaceutical Chemistry Journal, 2024, v. 58, n. 8, p. 1273, doi. 10.1007/s11094-024-03270-3
- By:
- Publication type:
- Article
Molecular Structure, Spectroscopic Investigation, Docking and in Vitro Cytotoxicity Studies of 7-Methoxycoumarin as anti-Leukemia Agent.
- Published in:
- Polycyclic Aromatic Compounds, 2022, v. 42, n. 10, p. 6988, doi. 10.1080/10406638.2021.1994430
- By:
- Publication type:
- Article
PROTAC for Bruton's tyrosine kinase degradation alleviates inflammation in autoimmune diseases.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Ibrutinib-induced pneumonitis in chronic lymphocytic leukemia patient.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Effective treatment of autoimmune thrombocytopenia with rituximab in CLL patient undergoing therapy with acalabrutinib.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Expert opinion on use of acalabrutinib for chronic lymphocytic leukemia treatment.
- Published in:
- Acta Haematologica Polonica, 2024, v. 55, n. 3, p. 130, doi. 10.5603/ahp.100523
- By:
- Publication type:
- Article